Modern approaches at the management of children with community-acquired pneumonia

Experts of The Union of Pediatricians of Russia have developed current clinical guidelines for management of children with community-acquired pneumonia, which were approved by the Scientific and Practice Council of Ministry of Public Health of the Russian Federation in January 2022. Particular attention is paid to the etiological structure, modern classification, diagnostic tests and flagship approaches to antibacterial therapy of community-acquired pneumonia in children based on the principles of evidentiary medicine. 

1. Geppe NA, Rozinova NN, Volkov IK, Mizernitskii YuL. Rabochaya klassifikatsiya osnovnykh klinicheskikh form bronkholegochnykh zabolevanii u detei. Trudnyi patsient. 2009;7(1-2):35–39. (In Russ).

2. Bradley JS, Byington CL, Shah SS, et al. Executive summary: the management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):617–630. doi: https://doi.org/10.1093/cid/cir625

3. Pocket book of hospital care for children: Guidelines for the management of common childhood illnesses. 2nd ed. Geneva: World Health Organization; 2013.

4. Vnebol’nichnaya pnevmoniya u detei: Clinical guidelines. Russian Respiratory Society; Interregional Pediatric Respiratory Society; Federation of Pediatricians of the CIS countries; Moscow Society of Pediatric Doctors. Moscow: Original-maket; 2015. 64 p. (In Russ).

5. Michelow IC, Olsen K, Lozano J, et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics. 2004;113(4):701–707. doi: https://doi.org/10.1542/peds.113.4.701

6. Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372(9):835–845. doi: https://doi.org/10.1056/NEJMoa1405870

7. Yun KW, Wallihan R, Juergensen A, et al. CommunityAcquired Pneumonia in Children: Myths and Facts. Am J Perinatol. 2019;36(S02):S54–S57. doi: https://doi.org/10.1055/s-0039-1691801

8. Kaz SE, Wiliams D. Pediatric community-acquired pneumonia in the United States: changing epidemiology, diagnostic and therapeutic challenges, and areas for future research. Infect Dis Clin North Am. 2018;32(1):47–63. doi: https://doi.org/10.1016/j.idc.2017.11.002

9. Gareca Perales J, Soleto Ortiz L, Loayza Mafayle R, et al. Diagnosis of Community-acquired Pneumonia in Hospitalized Children. A Multicenter Experience in Bolivia. Pediatr Infect Dis J. 2021;40(1):32–38. doi: https://doi.org/10.1097/INF.0000000000002909

10. Rhedin S, Lindstrand A, Hjelmgren A, et al. Respiratory viruses associated with community-acquired pneumonia in children. Matched Case-Control study. Thorax. 2015;70(9):847–853. doi: https://doi.org/10.1136/thoraxjnl-2015-206933

11. Tatochenko VK, Fedorov AM, Krasnov MV, et al. Ostrye pnevmonii u detei. Tatochenko VK, ed. Cheboksary: Chuvash University Press; 1994. 323 p. (In Russ).

12. Pritt BS, Aubry MC. Histopathology of viral infections of the lung. Semin Diagn Pathol. 2017;34(6):510–517. doi: https://doi.org/10.1053/j.semdp.2017.06.005

13. Samsonova MV, Chernyaev AL, Mikhaleva LM, et al. Patologicheskaya anatomiya legkikh pri COVID-19. (In Russ). https://patologoanatom.belzdrav.ru/upload/0_patologoanatom/covid-19/0605/mv_samsonova_covid-19_.pdf.

14. Stoll BJ, Hansen NI, Higgins RD, et al. Very low birth weight preterm infants with early onset neonatal sepsis: the predominance of gram-negative infections continues in the National Institute of Child Health and Human Development Neonatal Research Network, 2002–2003. Pediatr Infect Dis J. 2005;24(7):635–639. doi: https://doi.org/10.1097/01.inf.0000168749.82105.64

15. Mishaan AM, Mason EO Jr, Martinez-Aguilar G, et al. Emergence of a predominant clone of community-acquired Staphylococcus aureus among children in Houston, Texas. Pediatr Infect Dis J. 2005;24(3):201–206. doi: https://doi.org/10.1097/01.inf.0000151107.29132.70

16. Proportions of child death by cause: Global Health Observatory. Geneva: World Health Organization; 2014.

17. Kucova P, Kantor L, Fiserova K, et al. Bacterial Pathogens and Evaluation of a Cut-Off for Defining Early and Late Neonatal Infection. Antibiotics (Basel). 2021;10(3):278. doi: https://doi.org/10.3390/antibiotics10030278

18. Nascimento-Carvalho CM, Ribeiro CT, Cardoso MR, et al. The role of respiratory viral infections among children hospitalized for community-acquired pneumonia in a developing country. Pediatr Infect Dis J. 2008;27(10):939–941. doi: https://doi.org/10.1097/INF.0b013e3181723751

19. American Academy of Pediatrics Committee on Infectious Diseases. Recommended childhood and adolescent immunization schedules — United States, 2009. Pediatrics. 2009;123(1):189– 190. doi: https://doi.org/10.1542/peds.2008-3306

20. Tsolia MN, Psarras S, Bossios A, et al. Etiology of communityacquired pneumonia in hospitalized school-age children: evidence for high prevalence of viral infections. Clin Infect Dis. 2004;39(5):681–686. doi: https://doi.org/10.1086/422996

21. Tajima T, Nakayama E, Kondo Y, et al. Etiology and clinical study of community-acquired pneumonia in 157 hospitalized children. J Infect Chemother. 2006;12(6):372–379. doi: https://doi.org/10.1007/s10156-006-0476-5

22. Marangu D, Zar HJ. Childhood pneumonia in low-and-middleincome countries: An update. Paediatr Respir Rev. 2019;32:3–9. doi: https://doi.org/10.1016/j.prrv.2019.06.001

23. Esposito S, Patria MF, Tagliabue C, et al. CAP in chil-dren. In: European Respiratory Monograph 63: Community-Acquired Pneumonia. Chalmers J, Pletz M, Aliberti S, eds. 2014. pp. 130– 139.

24. Kuzmenkov AYu, Trushin IV, Avramenko AA, et al. AMRmap: an online platform for monitoring antibiotic resistance. Clinical Microbiology and Antimicrobial Chemotherapy. 2017;19(2):84–90. (In Russ).

25. Baranov A, Namazova L, Tatochenko V. Pneumococcal infection and associated diseases — a serious problem of modern health care. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2008;5(1):7–12. (In Russ).

26. Kozlov RS, Sinopalnikov AI, Zaitseva OV, et al. Inhibitor-protected amoxicillin with increased amoxicillin content and active ingredients ratio of 14:1: the use for treatment of community-acquired respiratory infections and ENT infections in children. Expert Council resolution. Clinical Review for General Practice. 2021;2:6–14. (In Russ). doi: https://doi.org/10.47407/kr2021.2.1.00036

27. Torumkuney D, Mayanskiy N, Edelstein M, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2014–16 in Russia. J Antimicrob Chemother. 2018;73(Suppl_5):v14–v21. doi: https://doi.org/10.1093/jac/dky065

28. Ivanova OV, Edelstein IA, Romashov OI, Kozlov RS. Effect of 23S rRNA gene mutations in Mycoplasma pneumoniae on severity of community-acquired pneumonia in young adult patients treated at the Smolensk military hospital. Clinical Microbiology and Antimicrobial Chemotherapy. 2020;22(4):306–312. (In Russ). doi: https://doi.org/10.36488/cmac.2020.4.306-312

29. Prevalence of macrolide and fluoroquinolone resistancemediating mutations in Mycoplasma genitalium and Mycoplasma pneumoniae. In: AMRcloud. April 08, 2021. (In Russ). https://amrcloud.net/ru/project/demares. Ссылка активна на 14.02.2022.

30. Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H. Global estimate of the incidence of clinical pneumonia among children under five years of age. Bull World Health Organ. 2004;82(12):895–903.

31. The incidence of the population of Russia in 2000–2009. Statistical materials of the Ministry of Health and Social Development of the Russian Federation. (In Russ).

32. Kozlov RS, Krechikova OI, Muravyev AA, et al. Incidence of Community-Acquired Pneumonia and Acute Otitis Media in Children 0–5 Years in Russia and Role of S. pneumoniae or H. influenzae in the Etiology of the Diseases. Clinical Microbiology and Antimicrobial Chemotherapy. 2013;15(4):246–260. (In Russ).

33. Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66 Suppl 2;ii1–23. doi: https://doi.org/10.1136/thoraxjnl-2011-200598

34. Levels and trends in child mortality: Report 2014. United Nations Inter Agency Group for Child Mortality Estimation. UNICEF, WHO, The World Bank, United Nations Population Divisoin. New York; 2014.

35. Revised WHO classification and treatment of childhood pneumonia at health facilities: evidence summaries. Geneva: World Health Organization; 2014.

36. Wingerter SL, Bachur RG, Monuteaux MC, Neuman MI. Application of the World Health Organization criteria to predict radiographic pneumonia in a US-based pediatric emergency department. Pediatr Infect Dis J. 2012;31(6):561–564. doi: https://doi.org/10.1097/INF.0b013e31824da716

37. Tatochenko VK. Bolezni organov dykhaniya u detei. 7th ed. Moscow: Borges; 2019. 300 p. (In Russ).

38. Rambaud-Althaus C, Althaus F, Genton B, D’Acremont V. Clinical features for diagnosis of pneumonia in children younger than 5 years: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(4):439–450. doi: https://doi.org/10.1016/S1473-3099(15)70017-4.

39. Ginsburg AS, Lenahan JL, Izadnegahdar R, Ansermino JM. A Systematic Review of Tools to Measure Respiratory Rate in Order to Identify Childhood Pneumonia. Am J Respir Crit Care Med. 2018;197(9):1116–1127. doi: https://doi.org/10.1164/rccm.201711-2233CI

40. Boyd K. Back to the Basics: Community-Acquired Pneumonia in Children. Pediatr Ann. 2017;46(7):e257–e261. doi: https://doi.org/10.3928/19382359-20170616-01

41. Søndergaard MJ, Friis MB, Hansen DS, Jørgensen IM.. Clinical manifestations in infants and children with Mycoplasma pneumoniae infection. PLoS One. 2018;13(4):e0195288. doi: https://doi.org/10.1371/journal.pone.0195288

42. Manerov FK. Diagnostika i terapiya ostroi pnevmonii u detei pri raznykh variantakh techeniya. [dissertation]. Novokuznetsk; 1990. (In Russ).

43. Tatochenko VK. Community-acquired pneumonia in children — problems and solutions. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2021;66(1):9–21. (In Russ). doi: https://doi.org/10.21508/1027-4065-2021-66-1-9-21

44. Mcintosh K. Community-Acquired pneumonia in children. N Engl J Med. 2002; 346(6): 429–437. doi: https://doi.org/10.1056/NEJMra011994

45. Crawford SE, Daum RS. Bacterial pneumonia, lung abscess and empyema. In: Pediatric respiratory medicine. Taussig LM, Landau LI, eds. 2nd ed. Mosby, Inc.; 2008. pp. 501–553. doi: https://doi.org/10.1016/B978-032304048-8.50039-6

46. Bakradze MD, Kulichenko TV, Mityushin IL, et al. Likhoradyashchii rebenok. Baranova AA, et al. Moscow: Pediatr; 2017. 320 p. (In Russ).

47. Goodman D, Crocker ME, Pervaiz F. Challenges in the diagnosis of paediatric pneumonia in intervention field trials: recommendations from a pneumonia field trial working group. Lancet Respir Med. 2019;7(12):1068–1083. doi: https://doi.org/10.1016/S2213-2600(19)30249-8

48. Thomas J, Pociute A, Kevalas R, et al. Blood biomarkers differentiating viral versus bacterial pneumonia aetiology: a literature review. Ital J Pediatr. 2020;46(1):4. doi: https://doi.org/10.1186/s13052-020-0770-3

49. Iroh Tam PY, Bernstein E, Ma X, Ferrieri P. Blood Culture in Evaluation of Pediatric Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Hosp Pediatr. 2015;5(6):324–336. doi: https://doi.org/10.1542/hpeds.2014-0138

50. Bhuiyan MU, Blyth CC, West R. Combination of clinical symptoms and blood biomarkers can improve discrimination between between bacterial or viral community-acquired pneumonia in children. BMC Pulm Med. 2019;19(1):71. doi: https://doi.org/10.1186/s12890-019-0835-5

51. ERS handbook of paediatric respiratory medicine. Eber E, Midulla F, eds. Sheffield: European Respiratory Society; 2013. 719 p.

52. Hosseini SM, Poorolajal J, Karami M, Ameri P. Prevalence of Nasopharyngeal Carriage of Streptococcus pneumonia in Iran: A Meta-Analysis. J Res Health Sci. 2015;15(3):141–146.

53. Johnson HL, Deloria-Knoll M, Levine OS, et al. Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med. 2010;7(10):e1000348. doi: https://doi.org/10.1371/journal.pmed.1000348

54. Fernando M de Benedictis FM, Kerem E, Chang AB, et al. Complicated pneumonia in children. Lancet. 2020;396(10253):786– 798. doi: https://doi.org/10.1016/S0140-6736(20)31550-6

55. Profilaktika, diagnostika i lechenie novoi koronavirusnoi infektsii (COVID-19): temporary guidelines. Version 11 from 05/07/2021 (In Russ).

56. Osobennosti klinicheskikh proyavlenii i lecheniya zabolevaniya, vyzvannogo novoi koronavirusnoi infektsiei (COVID-19) u detei: temporary guidelines. Version 2 from 03/07/2021 (In Russ).

57. Uchaykin VF, Spichak TV, Kim SS, et al. Revealing of respiratory viruses and atypical bacteria in children with pneumonia and healthy children for ten years of observation. Pediatria. Journal n.a. G.N. Speransky. 2016;95(2):43–50. (In Russ).

58. Spuesens EB, Fraaij PL, Visser EG, et al. Carriage of Mycoplasma pneumoniae in the upper respiratory tract of symptomatic and asymptomatic children: an observational study. PLoS Med. 2013;10(5):e1001444. doi: https://doi.org/10.1371/journal.pmed.1001444

59. Copete AR, Vera C, Herrera M, et al. Mycoplasma pneumoniae in children with and without community-acquired pneumonia. What do PCR and serology say? Pediatr Infect Dis J. 2020;39(7):e104– e108. doi: https://doi.org/10.1097/INF.0000000000002636.

60. Guiso N, Berbers G, Fry NK, et al. What to do and what not to do in serological diagnosis of pertussis: recommendations from EU reference laboratories. Eur J Clin Microbiol Infect Dis. 2011;30(3):307–312. doi: https://doi.org/10.1007/s10096-010-1104-y

61. Dean P, Florin TA. Factors Associated With Pneumonia Severity in Children: A Systematic Review. J Pediatric Infect Dis Soc. 2018;7(4):323–334. doi: https://doi.org/10.1093/jpids/piy046

62. Andronikou S, Lambert E, Halton J, et al. Guidelines for the use of chest radiographs in community-acquired pneumonia in children and adolescents. Pediatr Radiol. 2017;47(11):1405–1411. doi: https://doi.org/10.1007/s00247-017-3944-4

63. Le Roux DM, Zar HJ. Community-acquired pneumonia in children — a changing spectrum of disease. Pediatr Radiol. 2017;47(11):1392–1398. doi: https://doi.org/10.1007/s00247-017-3827-8

64. Levinsky Y, Mimouni FB, Fisher D, Ehrlichman M. Chest radiography of acute paediatric lower respiratory infections: experience versus interobserver variation. Acta Paediatr. 2013;102(7):e310–e314. doi: https://doi.org/10.1111/apa.12249

65. Nascimento-Carvalho CM, Araújo-Neto CA, Ruuskanen O. Association between bacterial infection and radiologically confirmed pneumonia among children. Pediatr Infect Dis J. 2015;34(5):490– 493. doi: https://doi.org/10.1097/INF.0000000000000622

66. Novack V, Avnon LS, Smolyakov A, et al. Disagreement in the interpretation of chest radiographs among specialists and clinical outcomes of patients hospitalized with suspected pneumonia. EurJ Intern Med. 2006;17(1):43–47. doi: https://doi.org/10.1016/j.ejim.2005.07.008

67. Johnson J, Kline JA. Intraobserver and interobserver agreement of the interpretation of pediatric chest radiographs. Emerg Radiol. 2010;17(4):285–290. doi: https://doi.org/10.1007/s10140-009-0854-2

68. Weigl J. Community acquired pneumonia in Germany. In: 21th Annual Meeting of ESPID, Taormina, Sicily, April 9–12, 2003. Abstr. 47. p. 24.

69. Orso D, Ban A, Guglielmo N. Lung ultrasound in diagnosing pneumonia in childhood: a systematic review and meta-analysis. J Ultrasound. 2018;21(3):183–195. doi: https://doi.org/10.1007/s40477-018-0306-5

70. El Fahimi N, Calleja MA, Ratnayake L, Ali I. Audit of a multidisciplinary approach to improve management of communityacquired pneumonia. Eur J Hosp Pharm. 2019;26(4):223–225. doi: https://doi.org/10.1136/ejhpharm-2017-001368

71. Lodha R, Kabra SK, Pandey RM. Antibiotics for communityacquired pneumonia in children. Cochrane Database Syst Rev. 2013;2013(6):CD004874. doi: https://doi.org/10.1186/1471- 2431-9-15

72. Infants and Children: Acute Management of Community Acquired Pneumonia: Guideline. NSW Health; 2018. Available online: https://www1.health.nsw.gov.au/pds/ActivePDSDocuments/GL2018_007.pdf. Accessed on February 15, 2023.

73. Amoxicillin Dispertab®. Registration certificate No. ЛП-006567. Registration date: November 13, 2022. In: State Register of Medicines: official website. (In Russ). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=3235dc2e-7f7b-4d14-875dfe3e1d5a66b1.

74. Amosin®. Registration certificate No. ЛС-001736. Registration date: August 13, 2010. In: State Register of Medicines: official website. (In Russ). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=55024c57-ba7a-4584-bfa7-a1a0ab61da4d.

75. Aurangzeb B., Hameed A. Comparative efficacy of amoxicillin, cefuroxime and clarithromycin in the treatment of communityacquired pneumonia in children. J Coll Physicians Surg Pak. 2003;13(12):704–707.

76. Wubbel L, Muniz L, Ahmed A, et al. Etiology and treatment of community-acquired pneumonia in ambulatory children. Pediatr Infect Dis J. 1999;18(2):98–104. doi: https://doi.org/10.1097/00006454-199902000-00004

77. Schönwald S, Gunjaca M, Kolacny-Babić L, et al. Comparison of azithromycin and erythromycin in the treatment of atypical pneumonias. J Antimicrob Chemother. 1990;25 Suppl A:123–126. doi: https://doi.org/10.1093/jac/25.suppl_a.123

78. Ushkalova EA. Primenenie doksitsiklina u detei i podrostkov. Farmateka. 2005;(15):18. (In Russ).

79. Chiappini E, Mazzantini R, Bruzzese E, et al. Rational use of antibiotics for the management of children’s respiratory tract infections in the ambulatory setting: an evidence-based consensus by the Italian Society of Preventive and Social Pediatrics. Paediatr Respir Rev. 2014;15(3):231–236. doi: https://doi.org/10.1016/j.prrv.2013.11.011

80. Mathur S, Fuchs A, Bielicki J, et al. Antibiotic use for communityacquired pneumonia in neonates and children: WHO evidence review. Paediatr Int Child Health. 2018;38(Supp1):S66–S75. doi: https://doi.org/10.1080/20469047.2017.1409455

81. Matsubara K, Morozumi M, Okada T, et al. A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients. J Infect Chemother. 2009;15(6):380–383. doi: https://doi.org/10.1007/s10156-009-0715-7

82. Lee H, Yun KW, Lee HJ, Choi EH. Antimicrobial therapy of macrolide-resistant Mycoplasma pneumoniae pneumonia in children. Expert Rev Anti Infect Ther. 2018;16(1):23–34. doi: https://doi.org/10.1080/14787210.2018.1414599

83. Leung AKC, Wong AHC, Hon KL. Community-Acquired Pneumonia in Children. Recent Pat Inflamm Allergy Drug Discov. 2018;12(2):136–144. doi: https://doi.org/10.2174/187221 3X12666180621163821

84. Cefuroxime. Registration certificate No. ЛП-000003. Registration date: Marth 02, 2007. State Register of Medicines: official website. (In Russ). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=ffcb5e06-1df5-4860-8d95-7bd11e4f869b.

85. Haider BA, Saeed MA, Bhutta ZA. Short-course versus longcourse antibiotic therapy for non- severe community-acquired pneumonia in children aged 2 months to 59 months. Cochrane Database Syst Rev. 2008;(2):CD005976. doi: https://doi.org/10.1002/14651858.CD005976.pub2

86. Zinforo®. Registration certificate No. ЛП-001912. Registration date: November 20, 2012. State Register of Medicines: official website. (In Russ). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=8035dfec-e622-4f1e-b152-c429567cb058.

87. Cannavino CR, Nemeth A, Korczowski B, et al. A Randomized, Prospective Study of Pediatric Patients With Community-acquired Pneumonia Treated With Ceftaroline Versus Ceftriaxone. Pediatr Infect Dis J. 2016;35(7):752–759. doi: https://doi.org/10.1097/INF.0000000000001159

88. Pneumonia (community-acquired): antimicrobial prescribing. NICE guideline [NG138]. September 2019. Available online: https://www.nice.org.uk/guidance/ng138. Accessed on February 15, 2023.

89. Nascimento-Carvalho CM. Community-acquired pneumonia among children: the latest evidence for an updated management. J Pediatr (Rio J). 2020;96(Suppl 1):29–38. doi: https://doi.org/10.1016/j.jped.2019.08.003

90. Pernica JM, Harman S, Kam AJ, et al. Short-course antimicrobial therapy for pediatric community-acquired pneumonia. The SAFER randomized clinical trial. JAMA Pediatr. 2021;175(5):475–482. doi: https://doi.org/10.1001/jamapediatrics.2020.6735

91. Same RG, Amoah J, Hsu AJ, et al. The Association of Antibiotic Duration With Successful Treatment of Community-Acquired Pneumonia in Children. J Pediatric Infect Dis Soc. 2021;10(3):267– 273. doi: https://doi.org/10.1093/jpids/piaa055

92. Blaschke AJ, Heyrend C, Byington CL, et al. Molecular analysis imroves pathogen identification and epidemiologic study of pediatric parapneumonic empyema. Pediatr Infect Dis J. 2011;30(4):289– 294. doi: https://doi.org/10.1097/INF.0b013e3182002d14

93. Bradley JS, Ching DK, Hart CL. Invasive bacterial disease in childhood: efficacy of oral antibiotic therapy following short course parenteral therapy in non-central nervous system infections. Pediatr Infect Dis J. 1987;6(9):821–825.

94. Moreno-Pérez D, Andrés Martín A, Tagarro García A, et al. Community acquired pneumonia in children: Treatment of complicated cases and risk patients. Consensus statement by the Spanish Society of Paediatric Infectious Diseases (SEIP) and the Spanish Society of Paediatric Chest Diseases (SENP). An Pediatr (Barc). 2015;83(3):217.e1–11. doi: https://doi.org/10.1016/j.anpedi.2014.12.002

95. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev. 2014;4:CD008965. doi: https://doi.org/10.1002/14651858.CD008965.pub3

96. Heneghan CJ, Onakpoya I, Jones MA, et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess. 2016;20(42):1–242. doi: https://doi.org/10.3310/hta20420

97. Relenza. Registration certificate No. ЛСР-000095. Registration date: May 31, 2007. State Register of Medicines: official website. (In Russ). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=5edcae9f-e8f3-4227-9939-e5aa7fdf1e9b.

98. Thorlund K, Awad T, Boivin G, Thabane L. Systematic review of influenza resistance to the neuraminidase inhibitors. BMC Infect Dis. 2011;11:134. doi: https://doi.org/10.1186/1471-2334-11-134

99. Nurofen® for children. Registration certificate No. П N014745/01. Registration date: August 22, 2008. State Register of Medicines: official website. (In Russ). https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=58ea2be8-b33b-4924-9fab97a5825084a6.

100. Rukovodstvo po ambulatorno-klinicheskoi pediatrii. Baranov AA, ed. 2nd ed. Moscow: GEOTAR-Media; 2009. (In Russ).

101. Feld LG, Neuspiel DR, Foster BA, et al. Clinical Practice Guideline: Maintenance Intravenous Fluids in Children. Pediatrics. 2018;142(6):e20183083. doi: https://doi.org/10.1542/peds.2018-3083

102. Duke T, Molyneux EM. Intravenous fluids for seriously ill children: time to reconsider. Lancet. 2003;362(9392):1320–1323. doi: https://doi.org/10.1016/S0140-6736(03)14577-1

103. Barson WJ. Pneumonia in children: Inpatient treatment. In: UpToDate. Available online: https://www.uptodate.com/contents/pneumonia-in-children-inpatient-treatment?search=pneumonia%20acidosis&source=search_result&selectedTitle=2~150&usage_type=default. Accessed on February 15, 2023.

104. Ambroggio L, Test M, Metlay JP, et al. Adjunct Systemic Corticosteroid Therapy in Children With Community-Acquired Pneumonia in the Outpatient Setting. J Pediatric Infect Dis Soc. 2015;4(1):21–27. doi: https://doi.org/10.1093/jpids/piu017

105. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J. 1996;15(3):255– 259. doi: https://doi.org/10.1097/00006454-199603000-00015

106. Chang CC, Cheng AC, Chang AB. Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults. Cochrane Database Syst Rev. 2014;(3):CD006088. doi: https://doi.org/10.1002/14651858. CD006088.pub2

107. Stern A, Skalsky K, Avni T, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev. 2017;12(12):CD007720. doi: https://doi.org/10.1002/14651858.CD007720.pub3

108. Tagarro A, Otheo E, Baquero-Artigao F, et al. Dexamethasone for parapneumonic pleural effusion: a randomized, double-blind, clinical trial. J Pediatr. 2017;185:117–23.e6. doi: https://doi.org/10.1016/j.jpeds.2017.02.043

109. Das RR, Singh M, Naik SS. Vitamin D as an adjunct to antibiotics for the treatment of acute childhood pneumonia. Cochrane Database Syst Rev. 2018;7(7):CD011597. doi: https://doi.org/10.1002/14651858.CD011597.pub2

110. Hemilä H, Chalker E. Vitamin C for preventing and treating the common cold. Cochrane Database Syst Rev. 2013;2013(1):CD000980. doi: https://doi.org/10.1002/14651858.CD000980.pub4

111. Padhani ZA, Moazzam Z, Ashraf A, et al. Vitamin C supplementation for prevention and treatment of pneumonia. Cochrane Database Syst Rev. 2020;4(4):CD013134. doi: https://doi.org/10.1002/14651858.CD013134.pub2

112. Wu T, Ni J, Wei J. Vitamin A for non‐measles pneumonia in children. Cochrane Database Syst Rev. 2005;2005(3):CD003700. doi: https://doi.org/10.1002/14651858.CD003700.pub2

113. Brown N, Roberts C. Vitamin A for acute respiratory infection in developing countries: a meta‐analysis. Acta Paediatr. 2004;93(11):1437–1442. doi: https://doi.org/10.1080/08035250410022143

114. Kumar RM, Kabra SK, Singh M. Efficacy and acceptability of different modes of oxygen administration in children: implications for a community hospital. J Trop Pediatr. 1997;43(1):47–49. doi: https://doi.org/10.1093/tropej/43.1.47

115. Carter E, Waldhausen J, Zhang W, et al. Management of children with empyema: pleural drainage is not always necessary. Pediatr Pulmonol. 2010;45(5):475–480. doi: https://doi.org/10.1002/ppul.21200

116. Malyavin AG, Epifanov VA, Glazkova II. Reabilitatsiya pri zabolevaniyakh organov dykhaniya. Moscow: GEOTAR-Media; 2010. 352 p. (Biblioteka vracha-spetsialista). (In Russ).

117. Swingler GH, Michaels D, Hussey GGD. Conjugate vaccines for preventing Haemophilus influenzae type B infections. Cochrane Database Syst Rev. 2003;(4):CD001729. doi: https://doi.org/10.1002/14651858.CD00172

118. The Green Book. Immunization against infections disease. 2013. Part 2. Ch. 16. pp. 127–143.

119. Cox AD, Barreto L, Ulanova M, et al. Developing a vaccine for Haemophilus influenzae serotype a: Proceedings of a workshop. Can Commun Dis Rep. 2017;43(5):89–95. doi: https://doi.org/10.14745/ccdr.v43i05a02

120. Wiese AD, Griffin MR, Grijalva CG Impact of pneumococcal conjugate vaccines on hospitalizations for pneumonia in the United States. Expert Rev Vaccines. 2019;18(4):327–341. doi: https://doi.org/10.1080/14760584.2019.1582337

121. Lucero MG, Dulalia VE, Nillos LT, et al. Pneumococcal conjugate vaccines for preventing vaccine‐type invasive pneumococcal disease and X‐ray defined pneumonia in children less than two years of age. Cochrane Database Syst Rev. 2009;2009(4):CD004977. doi: https://doi.org/10.1002/14651858.CD004977.pub2

122. Sings HL, De Wals P, Gessner BD, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine against invasive disease caused by serotype 3 in children: a systematic review and metaanalysis of observational studies. Clin Infect Dis. 2019;68(12):2135– 2143. doi: https://doi.org/10.1093/cid/ciy920

123. Thompson A, Gurtman A, Patterson S, et al. Safety of 13-valent pneumococcal conjugate vaccine in infants and children: meta-analysis of 13 clinical trials in 9 countries. Vaccine. 2013;31(45):5289–5295. doi: https://doi.org/10.1016/j.vaccine.2013.08.025

124. Ewald H, Briel M, Vuichard D, et al. The clinical effectiveness of pneumococcal conjugate vaccines: a systematic review and meta-analysis of randomized controlled trials. Dtsch Arztebl Int. 2016;113(9):139–146. doi: https://doi.org/10.3238/arztebl.2016.0139

125. Jones LL, Hashim A, McKeever T, et al. Parental and household smoking and the increased risk of bronchitis, bronchiolitis and other lower respiratory infections in infancy: systematic review and meta-analysis. Respir Res. 2011;12(1):5. doi: https://doi.org/10.1186/1465-9921-12-5

126. Watererl G, Bennett L. Improving Outcomes From Communityacquired Pneumonia. Curr Opin Pulm Med. 2015;21(3):219–225. doi: https://doi.org/10.1097/MCP.0000000000000155

127. Gattarello S, Borgatta B, Sole-Violan J, et al. Investigators CIs. Decrease in mortality in severe community-acquired pneumococcal pneumonia: impact of improving antibiotic strategies (2000– 2013). Chest. 2014;146(1):22–31. doi: https://doi.org/10.1378/chest.13-1531

128. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med. 2004;164(6):637– 644. doi: https://doi.org/10.1001/archinte.164.6.637